Dopaminergic Modulation of CD4+CD25<sup>high</sup> Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy
Marco Cosentino(University of Insubria), Franca Marino(University of Insubria), María Trojano(University of Bari Aldo Moro), Maurizio Giorelli(ASL Roma), Carmela Pica(University of Bari Aldo Moro), Sergio Lecchini(University of Insubria), Emanuela Rasini(University of Insubria), Paolo Livrea(University of Bari Aldo Moro), Marco Ferrari(University of Insubria), Giancarlo Comi(University of Milan), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), R Bombelli(University of Insubria), Angelo Ghezzi
Cited by 45
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Multiple Sclerosis Severity Score
|Neurology|2005|959
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Evidence of early cortical atrophy in MS
|Neurology|2003|485